Nextcea, Inc. is a pharmaceutical service company dedicated to optimizing efficacy, minimizing toxicity, and ensuring the quality of drug products through all phases of drug development and biotherapeutic bioequivalence. Nextcea performs customized services in support of discovery, preclinical and clinical stage research and biological therapeutic development.
• Biotherapeutic Antibody / Bioconjugate Characterization
• Drug-Induced Phospholipidosis
• Efficacy and Safety Biomarkers
• Bio-Analytical FDA GLP Validation and Sample Analysis
• Cross-Species ADME
• PK & TK Analysis (non-GLP/GLP)
These services can be conducted as non-GLP or GLP studies. In-house platforms include µHPLC, UPLC, high resolution/ accuracy (Q-TOF MS/MS) and sensitivity (API 6500s) mass spectrometry.